Macrocyclic hepatitis C serine protease inhibitors
US8937041B2 · kind B2 · utility
2Cited by
58References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2011 |
| Grant date | Jan 20, 2015 |
| Priority date | — |
| Expiry date | Mar 21, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.